Despite the WHO declaring the end of the COVID-19 global emergency, millions still suffer from long COVID, with symptoms like fatigue and pain persisting post-infection. A new study reveals that lung inflammation may significantly contribute to these chronic symptoms, hindering the immune system's ability to heal lung tissue. Researchers found reduced peroxisomes in immune cells from long COVID patients, suggesting a pathway for treatment. The study shows promise with an FDA-approved drug that could improve lung recovery, highlighting the need for further research on long COVID's complex mechanisms.
Long COVID presents a wide range of symptoms, and its underlying cellular and molecular mechanisms are highly complex. One of the most significant gaps is identifying the specific mechanisms driving different types of long COVID. Understanding these drivers is crucial for developing targeted therapeutic strategies.
We discovered that lung tissue from individuals who succumbed to acute COVID or suffered from severe respiratory long COVID exhibited decreased levels of peroxisomes in a type of immune cell responsible for tissue healing.
We demonstrated that an FDA-approved drug can enhance lung recovery and reduce long COVID-related tissue damage,
Collection
[
|
...
]